REBEC

Public trial

Evaluation of inflammatory markers in patients undergoing a short-term aerobic exercise program while hospitalized due to acute exacerbation of COPD

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Health education actions to improve the quality of life of adults affected by syndrome

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Molding techniques and their impact on retention in removable dentures

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Social support of family caregivers of elderly people with high dependence: a quasi-experimental study

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of strength training on body composition, biochemical markers and quality of life in patients with chronic kidney disease

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Comparison of the Acute Effect of different types of motor and mental stimuli and combined under the mental, autonomic and motor function of the patient with Respiratory Disease a randomized clinical trial

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The use of lasers with antimicrobial drugs to treat infected wounds in people with diabetes: randomized clinical trial

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of respiratory muscle training on functional capacity in neurological patients

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of the temperature of the irrigant during root canal treatment in patients with the use of several irrigant agitation methods

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of desensitizing gel on sensitivity caused by dental bleaching

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical simulation for teaching of sexuality of individuals with spinal cord injuries

Date of registration: 03/26/2020 ^(mm/dd/yyyy)
Last approval date : 03/26/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Biomechanical changes of the ankle and foot and the professor's feet pain

Date of registration: 03/25/2020 ^(mm/dd/yyyy)
Last approval date : 03/25/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Laser on Perineal Pain realief after Vaginal Birth

Date of registration: 09/24/2019 ^(mm/dd/yyyy)
Last approval date : 03/25/2020 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Heart rate variability after heart surgery

Date of registration: 03/25/2020 ^(mm/dd/yyyy)
Last approval date : 03/25/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Physiological Mechanismsof Bariatric Surgery

Date of registration: 03/25/2020 ^(mm/dd/yyyy)
Last approval date : 03/25/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of preemptive analgesia and desensitization to control painful sensitivity after tooth bleaching

Date of registration: 03/25/2020 ^(mm/dd/yyyy)
Last approval date : 03/25/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Metagenomic analysis of the colony of bacteria from the intestine of premature babies undergoing treatment with Colostrotherapy treated by the Unified Health System (SUS): Intervention Study

Date of registration: 03/25/2020 ^(mm/dd/yyyy)
Last approval date : 03/25/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of fractional CO2 laser in vaginal atrophy in menopausal women compared to topical estrogen therapy

Date of registration: 03/25/2020 ^(mm/dd/yyyy)
Last approval date : 03/25/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Exercises to keep your lung and healthy heart

Date of registration: 03/24/2020 ^(mm/dd/yyyy)
Last approval date : 03/24/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical evaluation of a fluid material to cover tooth cavities with lesions close to the gum.

Date of registration: 03/24/2020 ^(mm/dd/yyyy)
Last approval date : 03/24/2020 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

10/13/2026

IgniteData and RealTime Partner to Streamline Clinical Data Transfer From eSource to Sponsor Systems

10/13/2026 | Andy Studna | Applied Clinical Trials

https://www.appliedclinicaltrialsonline.com/view/ignitedata-realtime-partner-streamline-clinical-data-transfer-esource-sponsor-systems

The partnership gives RealTime's network of more than 3,000 research sites access to the Archer platform for direct, automated data transfer from eSource to any sponsor electronic data capture system or data destination.

IgniteData and RealTime eClinical Solutions have announced a partnership that will allow research sites using RealTime's electronic source data (eSource) solution to transfer clinical data directly to a sponsor's electronic data capture (EDC) system or other data destination of choice through IgniteData's Archer platform.1

The collaboration is designed to reduce the manual transcription burden on site staff and shorten the time sponsors spend on data acquisition and monitoring.

RealTime supports more than 3,000 sites across more than 30 countries, with its Site Operations Management System (SOMS) used by nine of the ten largest site networks, three of the top five contract research organizations (CROs), and three major hospitals.

IgniteData's Archer platform is currently engaged at 80% of the National Cancer Institute's Designated Cancer Centers, including 19 of the top 30 cancer centers in the US, and spans a site network across four continents, six countries, and 11 international institutions.

For sites, the practical impact is straightforward: data captured once in RealTime's eSource platform flows automatically to the sponsor's system, removing the need for manual re-entry into each sponsor's EDC. That step, which research coordinators currently perform repeatedly across studies, is one…

10/12/2026

Phage Therapy Trials Are Launching Without a Regulatory Playbook. That’s a Problem.

10/12/2026 | Moe Alsumidaie | The Clinical Trial Vanguard

https://www.clinicaltrialvanguard.com/opinion/phage-therapy-trials-are-launching-without-a-regulatory-playbook-thats-a-problem/

Picture a protocol review committee sitting down with a Phase II bacteriophage therapy submission for recurrent, multidrug-resistant urinary tract infections. The science is compelling. The unmet need is real. And then someone asks the question that nobody has a clean answer to: what goes in the comparator arm? Standard-of-care antibiotics, against which resistance is literally the reason this trial exists? Placebo, which raises obvious ethical flags when patients are suffering through their fourth infection in twelve months? The room goes quiet, because the FDA has not published a specific guidance document for bacteriophage-based therapeutics, and the field is designing its most consequential trials on instinct rather than precedent.

That regulatory vacuum is not a footnote. As JAMA’s Medical News coverage of newly launched phage therapy trials for UTIs makes clear, this therapeutic class has arrived at the clinical testing stage carrying enormous promise and an unusual amount of structural uncertainty. Globally, approximately one in six laboratory-confirmed bacterial infections were resistant to antibiotic treatments in 2023, and between 2018 and 2023, antibiotic resistance increased in over 40% of monitored pathogen-antibiotic combinations, according to WHO surveillance data. UTIs sit squarely inside that crisis. What bacteriophage therapy offers is not just another drug mechanism, it is a fundamentally different biological logic, one that the existing clinical trial infrastructure was not built to accommodate.

The Mechanism the Field Is Betting On
Bacteriophages…

10/12/2026

AstraZeneca pins bone disease drug’s Phase III failure on high placebo response

10/12/2026 | Annabel Kartal Allen | Clinical Trials Arena

https://www.clinicaltrialsarena.com/news/astrazeneca-efzimfotase-alfa-hypophosphatase-phase-iii-hickory/

Despite the primary endpoint miss, AstraZeneca hopes to bring efzimfotase alfa to patients with hypophosphatasia.

AstraZeneca’s enzyme replacement therapy (ERT) candidate, efzimfotase alfa, has failed to demonstrate significant benefits over placebo in a late-stage trial in rare bone and muscle-targeting metabolic disease, hypophosphatasia (HPP).

This late-stage miss stems from the Phase III HICKORY study (NCT06079281), in which AstraZeneca’s rare disease arm, Alexion Pharmaceuticals, pitted efzimfotase alfa against placebo in adults and adolescents with HPP. Patients enrolled in this study had not received prior treatment with Alexion’s marketed enzyme replacement therapy, Strensiq (asfotase alfa).

During the trial, efzimfotase alfa offered a 17.05-meter baseline improvement in the six-minute walk test (6MWT) after 25 weeks of treatment. However, this value failed to trump the improvements in the same endpoint attained by patients in the placebo group, resulting in the trial missing its primary endpoint. In a statement, AstraZeneca called the placebo results from HICKORY “better-than-expected.”

Despite this primary endpoint miss, a post-hoc analysis of the study did reveal that 45.2% of patients treated with efzimfotase alfa achieved a minimum clinically important difference (MCID) from baseline in the 6MWT over 30% in the placebo arm. This means that treatment with efzimfotase alfa offered a 2.5-fold higher chance of a patient receiving a clinically meaningful response in the 6MWT, when MCID is classified as 31.1 and 43-meter improvements in walking distance within adults…

10/12/2026

Vietnamese scientists are researching technology for the early detection of cancer.

10/12/2026 | Education and Era Newspaper | Vietnam.VN

https://www.vietnam.vn/pt/nha-khoa-hoc-viet-nghien-cuu-cong-nghe-phat-hien-som-ung-thu

Vo Hong Phuc, a doctoral candidate at the University of Lübeck (Germany) and a former student at the Vietnam-Germany University, is researching PET technology for the early detection of cancer.

The turning point came during his internship.

Born in Ben Tre (formerly) and now Vinh Long, Vo Hong Phuc studied Electrical Engineering and Information Technology (EEIT), class of 2016, at the Vietnam-Germany University (Ho Chi Minh City). During his four years of college, he consistently received the VGU merit scholarship, which covered 50% of his tuition, and also won a scholarship from the German Academic Exchange Service (DAAD) to participate in a one-semester exchange program at Frankfurt University of Applied Sciences in Germany.

A turning point for Phuc occurred during his internship at a company, which shifted the focus of his research. He transitioned from pure electrical and electronic engineering to biomedical engineering, where technical knowledge can be directly applied in the healthcare field.

Determined to pursue this new field, after graduating from university, Phuc went to Germany to pursue a master’s degree in Biomedical Engineering in a joint program between the University of Lübeck and the Lübeck University of Applied Sciences, where he graduated with honors. Through his studies and thesis work, he gradually focused on nuclear medicine imaging, particularly on system simulation and the development of image reconstruction algorithms.

Continuing his scientific career, master’s student Vo Hong Phuc is a Ph.D. candidate at the Institute of Medical Technology at the University of Lübeck (Germany). He is involved in the…

10/12/2026

How AI Is Transforming Clinical Research in Brazil

10/11/2026 | Luis Salazar | Exame

https://exame.com/bussola/como-a-ia-esta-transformando-a-pesquisa-clinica-no-brasil/?utm_source=copiaecola&utm_medium=compartilhamento

The use of artificial intelligence and data science is making drug development faster, more precise, and more inclusive throughout Brazil

The development of a new drug or vaccine is, by its very nature, a journey that requires persistence. Traditionally, the path that takes a promising molecule from the laboratory bench to the pharmacy shelf or the hospital bed is long, complex, and challenging.

However, we are witnessing an unprecedented transformation in global clinical research, driven by a force that is redefining the frontiers of science: Artificial Intelligence (AI) and Data Science.

Far from being a futuristic promise, AI already serves as an essential cog in making medical research more agile, precise, and, above all, human.

Brazil is undergoing a transformative moment in this landscape. The recent modernization of our regulatory framework, combined with the enormous diversity of our population, has strategically positioned us on the map of healthcare innovation.

At MSD, we are not merely witnessing this evolution—we are at the center of it, investing in and leading the transformation that will accelerate the delivery of new therapies to the population.

Over the past five years, we have invested more than R$ 1 billion in clinical research in the country, a reflection of our long-term commitment. Today, we are conducting more than 120 clinical studies through an extensive network that spans more than 500 research centers across all regions of Brazil.

This robust ecosystem, involving more than 3,000 patients, drives scientific progress in the country.

…